Work

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.4098

Authors: Ahmed Omar Kaseb, Roberto Carmagnani Pestana, Luis M. Vence, Jorge M. Blando, Shalini Singh, Naruhiko Ikoma, Kanwal Pratap Singh Raghav, Divya Sakamuri, Lauren Girard, Dongfeng Tan, Jean-Nicolas Vauthey, Ching-Wei David Tzeng, Thomas A. Aloia, Yun Shin Chun, James C. Yao, Robert A. Wolff, James Patrick Allison, Padmanee Sharma

Institutions: The University of Texas MD Anderson Cancer Center, University of Kentucky

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4254031971

Cites:

Cited by: 7

Related to: 10